SCHEMBL5770474

SCHEMBL5770474

Cc1ccc(S(=O)(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)cc1CC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
MAPT P10636 3/20 0.63
ALDH1A1 P00352 2/20 0.63
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
CXCR3 P49682 1/20 0.43
ATM Q13315 1/20 0.43
HTT P42858 1/20 0.43
PTGDR Q13258 1/20 0.43
HSD11B1 P28845 2/20 0.43
PKM P14618 1/20 0.43
ADRB1 P08588 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5487074 0.87 KDM4E (0.59) KDM4EMAPTALDH1A1PPARGPPARD
SCHEMBL5745816 0.85 LMNA (0.45) KDM4EMAPTALDH1A1PPARGPPARD
SCHEMBL6348135 0.84 KDM4E (0.66) KDM4EALDH1A1PPARGPPARDPPARA
SCHEMBL5748224 0.83 HTT (0.52) ALDH1A1MEN1KMT2AHTTPTGDR
SCHEMBL6349243 0.82 DRD2 (0.46) KDM4EMAPTALDH1A1L3MBTL1LMNA
SCHEMBL5750293 0.82 PPARD (0.49) MAPTPPARDPPARAMEN1KMT2A
SCHEMBL5772894 0.81 HSD11B1 (0.62) MAPTALDH1A1LMNAMEN1POLB
SCHEMBL5776920 0.81 LMNA (0.51) MAPTLMNAMEN1POLBKMT2A
SCHEMBL5770088 0.80 HSD11B1 (0.66) HSD11B1
SCHEMBL6346332 0.80 ALDH1A1 (0.52) KDM4EALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD KDM4E 3692/4885MAPT 4579/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.